Gain Therapeutics To Present At Biotech Showcase 2025 [Yahoo! Finance]
Gain Therapeutics To Present At Biotech Showcase 2025
Gain Therapeutics, Inc. (NASDAQ: GANX) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Gain Therapeutics, Inc. (NASDAQ: GANX) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $7.00 price target on the stock.
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.